Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Crispr Therapeutics: I Sense A Long Bull Run As First Approval Approaches
02:52pm, Friday, 24'th Feb 2023
Crispr's share price spiked a little this week on Q422 earnings. There's a much bigger story unfolding, however - a first-ever approval of a Crispr/Cas9 gene editing cell therapy.
What Makes CRISPR Therapeutics AG (CRSP) a New Buy Stock
01:33pm, Friday, 24'th Feb 2023
CRISPR Therapeutics AG (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has CRISPR Therapeutics (CRSP) Outpaced Other Medical Stocks This Year?
11:18am, Friday, 24'th Feb 2023
Here is how CRISPR Therapeutics AG (CRSP) and Applied Molecular Transport Inc. (AMTI) have performed compared to their sector so far this year.
CRISPR (CRSP) Q4 Earnings Surpass Estimates, Sales Miss
02:18pm, Wednesday, 22'nd Feb 2023
CRISPR Therapeutics' (CRSP) fourth-quarter 2022 loss is narrower than expected, while sales miss estimates.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Tuesday, 21'st Feb 2023
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of 39.22% and 99.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the sto
2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer
09:07am, Saturday, 18'th Feb 2023
These two companies are on track to flourish through the end of the decade.
Beat the Dow Jones With CRISPR Therapeutics Stock
02:00pm, Friday, 17'th Feb 2023
If approved, CRISPR's first product may deliver blockbuster sales.
CRISPR Therapeutics AG (CRSP) SVB Securities Global Biopharma Conference (Transcript)
12:15am, Thursday, 16'th Feb 2023
CRISPR Therapeutics AG (NASDAQ:CRSP ) SVB Securities Global Biopharma Conference Call February 15, 2023 1:40 PM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participa
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
08:30am, Friday, 10'th Feb 2023
The gene-editing business has loads of potential, but is it enough to make you rich?
Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals?
05:56am, Thursday, 09'th Feb 2023
Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.
Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen.
05:30am, Thursday, 09'th Feb 2023
CRISPR shares are ripe for a rebound after dropping 46% last year.
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 08'th Feb 2023
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser
Ready to Buy the Dip? Consider This Gene Editing Stock
08:15am, Monday, 06'th Feb 2023
CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.
3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129%
05:55am, Monday, 06'th Feb 2023
Cathie Wood is bullish about these stocks. And so are Wall Street analysts.
3 No-Brainer Growth Stocks to Buy in 2023
02:00pm, Friday, 03'rd Feb 2023
These stocks all fell by double digits last year.
